Special Issue "Emerging Challenges in the Diagnosis and Treatment of Alzheimer’s Disease: The Role of Neuroinflammation and Microglia Biomarkers"
Deadline for manuscript submissions: closed (15 June 2023) | Viewed by 2791
Interests: laboratory medicine; Vitamin D; biomarkers; neurodegeneration
Special Issues, Collections and Topics in MDPI journals
Special Issue in Diagnostics: Biomarkers for Predicting Treatment Response and Guiding Therapy in COVID-19 Patients
Special Issue in International Journal of Molecular Sciences: Neuro–Immune Interactions in Health and Disease
Special Issue in Diagnostics: Vitamin D as a Biomarker in the Standardization Era: A Clinical Point of View
Special Issue in Diagnostics: Advances in Laboratory Medicine
Special Issue in International Journal of Molecular Sciences: Biomarkers in Neoplastic and Degenerative CNS Diseases: Defining New Frontiers in Clinical Usefulness and Therapeutic Molecular Target
Although the diagnosis and treatment of Alzheimer’s Disease (AD) is becoming even more challenging every day, new insights into the pathogenesis of the disease have been discovered. Understanding molecular mechanisms underlying the development of the disease is of great importance in order to discover novel, effective strategies to care for patients, and to ameliorate the quality of life for them and their care-givers. Amyloid β (Aβ) and intracellular neurofibrillary tangles (NFTs) of Tau protein represent the hallmarks of AD, and Aβ overproduction is known to lead to AD. This has paved the way for the amyloid cascade hypothesis of AD pathogenesis, which posits that the neuronal damage in AD is sustained by Aβ overproduction. However, it seems that the amyloid cascade hypothesis cannot fully disclose AD pathogenesis (3). Different processes could be involved in AD pathophysiology, and neuroinflammation is one of the most studied. This phenomenon relies on the activation of microglia and is mediated by some molecules, including CX3CL1, which is a neuronal chemokine that is received at the site of microglia. Many in vitro and in vivo studies have demonstrated a potential role of CX3CL1 as a biomarker for diagnosis in the early stage of AD and as a biochemical target for potential therapeutic strategies. Unfortunately, controversial findings have been achieved. Further, the signalling pathway of CX3CL1 in relation to the onset and progression of AD has been not investigated, and it still remains unknown whether some transcription factors and inflammatory molecules are over- or under-expressed in AD models and AD patients.
The current Special Issue aims to collect original articles and review articles exploring the mechanisms by which neuron-to-glia communication through CX3CL1 can be involved in the pathogenesis of AD. Additionally, this Special Issue aims to establish whether the chemokine, or some molecules within its signalling pathway, can be used for early identification and treatment of AD.
Dr. Giulia Bivona
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Alzheimer’s Disease
- neurofibrillary tangles
- neuro-immune cross-talk